Your browser doesn't support javascript.
loading
Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients.
Cervero, Miguel; Torres, Rafael; Agud, Jose Luís; Alcázar, Victoria; Jusdado, Juan José; García-Lacalle, Concepción; Moreno, Santiago.
Afiliação
  • Cervero M; Department of Internal Medicine, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • Torres R; Department of Internal Medicine, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • Agud JL; Department of Internal Medicine, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • Alcázar V; Department of Endocrinology, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • Jusdado JJ; Department of Internal Medicine, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • García-Lacalle C; Department of Biochemistry, Severo Ochoa University Hospital, Leganés, Madrid, Spain.
  • Moreno S; Department of Infectious Diseases, Ramón y Cajal Hospital, University of Alcalá de Henares, IRYCIS, Madrid, Spain.
PLoS One ; 13(4): e0196201, 2018.
Article em En | MEDLINE | ID: mdl-29709013
ABSTRACT

OBJECTIVES:

Several studies have involved antiretroviral therapy in the pathogenesis of low bone mineral density (BMD), while others have not confirmed this association. In this study we analyze the impact of HIV status, traditional risk factors and antiretroviral therapy in BMD in an HIV-infected population living in Madrid. MATERIAL AND

METHODS:

We performed a cross-sectional analysis of 107 individuals infected with HIV and exposed to antiretroviral treatment to estimate the prevalence of decreased BMD. Bone mineral density of lumbar spine and femoral neck was measured by dual-energy X-ray absorptiometry. In a multivariate analysis variables related with HIV status, antiretroviral drugs and traditional risk factors were included.

RESULTS:

Low BMD was diagnosed in 63 participants (58.9%), including osteoporosis in 11 (10%). At least one cause of osteoporosis was identified in 43 patients (40%), with a deficiency of vitamin D in 86 (89%) and secondary hyperparathyroidism in 30 (28%). In multivariate analysis, increasing age, a treatment based on boosted PI and tenofovir DF, and previous exposure to tenofovir were identified as independent risk factors for a decreased BMD in both lumbar spine and femoral neck.

CONCLUSIONS:

We have confirmed a high prevalence of reduced BMD, which is favoured by ritonavir-boosted PI and TDF. Bone safety should continue to be evaluated in clinical trials and cohort studies in order to demonstrate that the new drugs offer additional advantages regarding the impact on BMD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Densidade Óssea / Infecções por HIV / HIV-1 / Fármacos Anti-HIV Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteoporose / Densidade Óssea / Infecções por HIV / HIV-1 / Fármacos Anti-HIV Idioma: En Ano de publicação: 2018 Tipo de documento: Article